Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Metrics to compare | PBDA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPBDAPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −2.2x | −0.7x | |
PEG Ratio | 0.06 | −0.02 | 0.00 | |
Price / Book | 0.0x | 2.7x | 2.6x | |
Price / LTM Sales | 0.0x | 37.5x | 3.2x | |
Upside (Analyst Target) | - | 232.7% | 44.1% | |
Fair Value Upside | Unlock | 17.3% | 8.2% | Unlock |